February 2021 New Drug Approvals
PEPAXTO indicated in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. (1)
NULIBRY, indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.(2)
AMONDYS 45, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. (3)
COSELA, indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). (4)
EVKEEZA, indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH). (5)
UKONING, indicated for the treatment of adult patients with:(1). Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen ;(2)Relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.(6)
TEPMETKO, indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal epithelial transition (MET) exon 14 skipping alterations.(7)